Levothyroxine Treatment of Euthyroid Children with Autoimmune Hashimoto Thyroiditis: Results of a Multicenter, Randomized, Controlled Trial by Dörr, Helmuth G. et al.
E-Mail karger@karger.com
 Original Paper 
 Horm Res Paediatr 2015;84:266–274 
 DOI: 10.1159/000437140 
 Levothyroxine Treatment of Euthyroid Children 
with Autoimmune Hashimoto Thyroiditis: Results 
of a Multicenter, Randomized, Controlled Trial 
 Helmuth G. Dörr a    Markus Bettendorf b    Gerhard Binder c    Beate Karges d    
Carolin Kneppo b    Heinrich Schmidt e    Egbert Voss f    Martin Wabitsch g    
Jörg Dötsch h  
 a  Division of Paediatric Endocrinology and Diabetes, Department of Paediatrics, University of Erlangen,  Erlangen , 
 b  Division of Paediatric Endocrinology and Diabetes, Department of Paediatrics, University of Heidelberg, 
 Heidelberg ,  c  Paediatric Endocrinology, University Children’s Hospital, University of Tübingen,  Tübingen ,  d  Division 
of Endocrinology and Diabetes, Medical Faculty, RWTH Aachen University,  Aachen ,  e  Paediatric Endocrinology,
Dr. von Haunersches Kinderspital, University of Munich,  Munich ,  f  Cnopf’sche Kinderklinik,  Nuremberg ,  g  Division 
of Paediatric Endocrinology and Diabetes, Department of Paediatrics, University of Ulm,  Ulm , and  h  Department of 
Paediatrics, University of Cologne,  Cologne , Germany
 
globulin were assessed every 6 months for 36 months.  Re-
sults: At the start, the mean thyroid volume (standard de-
viation score, SDS) was 2.5 in the treatment group and 1.6 
in the observation group. There was a constant decline in 
mean thyroid volume (SDS) from 2.13 (month 12) to 1.12 
(month 30) in the treated group, with a delta thyroid volume 
of –1.01 SDS. In the observation group, the mean delta thy-
roid volume increased to +0.27 SDS. The change of the del-
ta thyroid volume was statistically significantly different be-
tween both groups during the 12- and 30-month time 
points (p < 0.05). L-T4 had no effect on thyroid function and 
serum thyroid antibodies.  Conclusions: L-T4 treatment can 
decrease the thyroid volume in euthyroid children with HT, 
but the effect is limited to a definite time period. 
 © 2015 S. Karger AG, Basel 
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 Abstract 
 Background: Levothyroxine (L-T4) treatment of euthyroid 
children with Hashimoto thyroiditis (HT) is a controversial 
issue.  Patients and Methods: We conducted a prospective, 
randomized, controlled clinical trial. Out of 79 identified eu-
thyroid patients, 59 started the study; 25 patients (21 fe-
male, 4 male; age: 11.8 ± 2.3 years) received L-T4 at a mean 
dose of 1.6 μg/kg (SD, 0.8) daily, and 34 (27 female, 7 male; 
age: 12.6 ± 1.2 years) were not treated. Patients developing 
subclinical hypothyroidism during follow-up (n = 13) were 
treated with L-T4 and removed from the observation group. 
As the main outcome measures, thyroid gland volume (de-
termined by ultrasound) as well as serum levels of TSH, free 
T4, and antibodies against thyroid peroxidase and thyro-
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 Hashimoto’s thyroiditis (HT) is the most common ac-
quired thyroid disease in children and adolescents  [1–3] . 
At the time of diagnosis, children and adolescents may be 
asymptomatic or may be referred with goiter and/or
hypothyroid symptoms  [4–6] . Diagnosis is based on
the presence of antibodies against thyroid peroxidase 
(TPOAb) and/or thyroglobulin (TgAb) and characteris-
tic sonographic features such as diffuse glandular en-
largement with coarse, heterogeneous and hypoechoic 
parenchymal echo pattern  [2, 7–9] .
 The clinical course of the disease is highly variable. 
There is no doubt that patients with overt hypothyroidism 
should receive treatment with levothyroxine (L-T4). It has 
been shown that L-T4 treatment of hypothyroid patients 
with HT also causes a reduction in the thyroid gland vol-
ume  [10, 11] . However, there is still controversy as to 
whether children with subclinical hypothyroidism (par-
ticularly those with normal serum free T4 (fT4) and TSH 
concentrations <10 mU/l) should be electively treated 
with L-T4  [5, 12, 13] , while there is no clear-cut recom-
mendation for the treatment of euthyroid children with 
HT. Rother et al.  [14] found an unchanged thyroid size in 
all children and adolescents treated with L-T4, and a study 
from Thailand demonstrated that euthyroid children with 
HT had normal growth and puberty without L-T4  [10] . 
The decision whether to treat or not to treat euthyroid 
children with HT should also consider the natural course 
of the disease. It has been shown that 64.8% of a group of 
105 euthyroid children with HT who were not treated with 
L-T4 still remained euthyroid after 5 years of follow-up 
 [15] . Studies in euthyroid adults with HT showed reduced 
serological and cellular markers of autoimmune thyroid-
itis after short-term prophylactic treatment  [16] and a re-
duction in the thyroid gland volume  [17] .
 The aim of the present study is to determine the effects 
of L-T4 on various parameters such as thyroid gland vol-
ume, thyroid antibodies, as well as TSH and fT4 levels in 
euthyroid subjects with HT. Therefore, we designed a 
prospective, randomized, open, controlled clinical trial at 
10 tertiary care centers for pediatric endocrinology in Ba-
varia and Baden-Württemberg, Germany.
 Patients and Methods 
 Patients 
 The study started at 10 centers [Augsburg, Erlangen, Heidel-
berg, Munich (2), Nuremberg, Stuttgart, Tübingen, Ulm, and 
Würzburg] in January, 2002, and was terminated in December, 
2009. Our intention was to study 120 euthyroid HT patients, 60 
with L-T4 and 60 without L-T4, during an observation period of 
60 months. However, for various reasons, e.g. insufficient re-
cruitment of patients by participating centers (only 6 out of 10 
centers provided patients), noncompliance, incomplete data and 
documentation, the overall aims of the study were not achieved, 
and the study was terminated earlier. Inclusion criteria were chil-
dren and adolescents aged 2–18 years, positive TPOAb and/or 
TgAb, euthyroid function, normal thyroid size or goiter with dis-
tinct sonographic features of HT, and the patients’ and parents’ 
written informed consent. Exclusion criteria were current treat-
ment with L-T4, type 1 diabetes, positive serum antibodies 
against TSH receptor, Turner or Down syndrome, and severe 
illness. Dropout criteria were noncompliance, withdrawal of 
consent, and L-T4 discontinuation for more than 2 weeks. The 
study protocol was approved by the Ethical Committee of the 
University of Erlangen and local institutional review boards, and 
the study was conducted in accordance with the Declaration of 
Helsinki.
 Study Protocol 
 We used an individually randomized, 2-group, parallel trial as 
study design. The euthyroid patients with HT were identified lo-
cally and reported to the study center in Erlangen where the ran-
dom allocation sequence was generated and the enrolled partici-
pants were assigned to the treatment group with L-T4 or to the 
observation group without treatment ( fig. 1 ).
 The thyroid volume was determined by ultrasound in each par-
ticipating center. All investigators were uniformly instructed 
about the definition of the measuring points before the start of the 
study. Thyroid-lobe height, width, and depth were examined with 
a 7.5-MHz linear transducer in transverse and longitudinal scans, 
and the volume of each thyroid lobe was calculated using the for-
mula proposed by Brunn et al.  [18] by multiplying the height, 
width, and thickness with 0.479. The thyroid volume was defined 
as the sum of the volumes of both lobes. The total thyroid volume 
was calculated in standard deviation score (SDS) values using pub-
lished reference data from the German KIGGS study where thy-
roid volume was determined in 6- to 17-year-old children and ad-
olescents (n = 9,175) by ultrasonography  [19, 20] . The following 
formula was used: 
 (measured thyroid volume – mean thyroid volume value of the 
reference population)/SD value of the reference population. 
 Patients were considered to be goitrous if they had a thyroid 
volume >2.0 SDS.
 L-T4 was given once daily p.o. in the morning, starting with a 
dose of 50 μg for patients with a body weight <50 kg, 75 μg for in-
dividuals with a body weight between 50 and 75 kg, 100 μg for pa-
tients with a body weight between 75 and 100 kg, and 150 μg for 
patients with a body weight >100 kg. The calculated L-T4 dose 
(mean ± SD) was 1.6 ± 0.8 μg/kg. If necessary, the L-T4 dose was 
adjusted to keep the TSH values within the desired range (0.5–4 
mU/l). Accordingly, the L-T4 dose was decreased in 4 patients and 
increased in 5 individuals. The baseline data of 59 euthyroid pa-
tients with HT (observation group: n = 34; treatment group: n = 
25) are shown in  table 1 . During the study, after an average of 14.7 
months, 13 individuals (mean age: 11.8 years) in the observation 
group showed subclinical hypothyroidism (TSH >6 mU/l; normal 
fT4) and were treated with L-T4 (group 3 in  table 1 ). Their data 
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 The clinical and laboratory assessment including clinical ex-
amination, ultrasound of the thyroid gland, measurement of thy-
roid hormones, and organ-specific autoantibodies (as specified be-
low) was performed at baseline and every 6 months until month 
60. However, when the study was stopped after 8 years, 36 months’ 
follow-up data were available in only 10 patients from each group. 
Since the evaluation of thyroid volume change might depend on 
the time points chosen, we decided to use the 30-month time point. 
The data at the 36-month time point could be biased due to the 
small number of patients and the loss of data of 6 patients.
 Table 1.  Clinical and laboratory data of the 59 euthyroid patients with HT at the start of the study (groups 1 and 2)
Group 1
(n = 34; 27 female, 7 male)
Group 2
(n = 25; 21 female, 4 male)
Group 3
(n = 13; 10 female, 3 male)
Chronological age, years 12.6 ± 2.4 (4.8 – 17.2) 11.8 ± 2.3 (7.7 – 15.4) 11.8 ± 2.1 (4.8 – 17.2)
Height, SDS 0.02 ± 1.02 0.36 ± 1.2 0.2 ± 1.2
BMI 19.3 ± 3.5 19.0 ± 3.1 18.0 ± 2.5
BMI, SDS 0.05 ± 1.1 0.2 ± 0.9  – 0.2 ± 1.1
L-T4 dosage, μg/kg/day – 1.6 ± 0.8 1.5 ± 0
TSH, mU/l 3.0 ± 1.5 3.0 ± 1.3 6.5 ± 1.7
fT4, pg/mla 13.5 ± 2.8 12.4 ± 2.2 11.6 ± 2.5
TPOAb, U/ml 1,057 ± 957 825 ± 1,015 2,073 ± 1,073
TgAb, U/ml 445 ± 753 545 ± 788 265 ± 244
Total thyroid volume, ml 10.8 ± 5.6 11.3 ± 6.6 11.6 ± 5.0
Thyroid volume, SDS 1.6 ± 2.1 2.5 ± 2.8 2.4 ± 3.2
Thyroid volume ≥2 SDS, % 24 47 30
 Data are shown as means ± SD. Group 1 = Observation group; group 2 = treatment group; group 3 = patients who became hypothyroid 
during the study. a fT4 pg/ml × 1.28 = pmol/l.
Assigned to ‘no L-T4’
(n = 40)
Age: 12.6 ± 1.2 years
(n = 34; 27 female, 7 male)
Euthyroid patients with HT
(n = 79)
Age: 13.5 ± 1.7 years
(n = 21; 17 female, 4 male)







data (n = 11)
Assigned to ‘L-T4’
(n = 39)
Age: 11.8 ± 2.3 years
(n = 25; 21 female, 4 male)





data (n = 15)
Start
R
 Fig. 1. Study design and assignment of 79 
euthyroid patients with HT who were ran-
domized to receive either L-T4 treatment 
or no treatment. R = Randomization. 
 *  Thirteen patients who became hypothy-
roid were removed from the study and 
treated with L-T4. 
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 For calculation of height and BMI SDS values, we used the Ger-
man reference data of Kromeyer-Hauschild et al.  [21] .
 Main Outcome Measures 
 Changes in thyroid gland volume (as determined by ultra-
sound), and changes in serum levels of TSH, thyroid hormones, 
TPOAb, and TgAb were assessed every 6 months for 36 months.
 Laboratory Measurements 
 TSH, fT4, and serum thyroid autoantibodies (TPOAb and TgAb) 
were determined using commercial immunometric reagent kits in 
each center. The following reference intervals were used: TSH (0.4–
4.5 mU/l), fT4 (10–23 pmol/l), TPOAb (<60 U/l), and TgAb (<60 U/l).
 Statistical Analysis 
 Parameters were compared between the treatment group and 
observation group using the Mann-Whitney U exact test. The dy-
namics of TSH, fT4, or thyroid volume in each group were calcu-
lated with nonparametric ANOVA for repeated measurements 
(Friedman test). All analyses involved two-tailed tests of significance 
and were performed using SPSS software (version 20; IBM, Ger-
many). p values <0.05 were considered to be statistically significant.
 Results 
 Study Population 
 Patients with HT presented to the participating centers 
with clinical symptoms consistent with thyroid dysfunc-
tion, a positive family history for HT, or were detected by 
chance. Data of patients fulfilling the inclusion criteria 
were sent anonymously to Erlangen, where the random-
ization process was started. Initially, 79 euthyroid pa-
tients with HT were identified, of whom 20 were lost by 
the first baseline visit. Thus, we were able to include 59 
euthyroid patients (48 female, 11 male) with HT in the 
study ( fig.  1 ). Relevant clinical and laboratory data are 
shown in  table 1 . The mean (±SD) chronological age of 
the patients with HT in the treatment group (n = 25) was 
11.8 ± 2.3 years and thus slightly lower than in the obser-
vation group (n = 34) where it was 12.6 ± 2.4 years. As 
shown in  table 1 , the baseline characteristics of the two 
groups were not significantly different. The patients who 
became hypothyroid during the study (group 3) had the 
same mean chronological age at the start of L-T4 as the 
patients who were treated from the very beginning of the 
study. Complete data were available for 10 patients in 
each group at the last follow-up at 36 months and used 
for a longitudinal analysis ( table 2 ).
 Table 2. Longitudinal changes in auxological parameters, thyroid hormones, autoantibody levels, and thyroid volumes of the 10 patients 
in each group who completed the study at baseline and after 12, 24, and 36 months (mean ± SD)
Group 1 (n = 10)  Group 2 (n = 10)
baseline 12 months 24 months 36 months  baseline 12 months 24 months 36 months
Chronological age, years 13.4 ± 1.58 14.5 ± 1.59 15.5 ± 1.66 16.6 ± 1.61 10.6 ± 2.50 11.8 ± 2.57 12.7 ± 2.46 13.7 ± 2.46
Height, SDS –0.11 ± 1.11 –0.33 ± 1.27 –0.12 ± 1.25 –0.66 ± 0.80 –0.21 ± 1.08 –0.07 ± 0.96 –0.08 ± 1.01 –0.26 ± 0.93
BMI, SDS 0.03 ± 0.83 0.22 ± 0.89 0.01 ± 0.86 0.43 ± 1.27 0.03 ± 0.73 0.03 ± 0.73 0.04 ± 0.90 0.02 ± 0.82
TSH, mU/l 2.41 ± 2.52 2.08 ± 0.82 2.33 ± 0.55 2.15 ± 0.63 3.51 ± 1.39 1.29 ± 1.08 1.43 ± 0.90 1.70 ± 1.33
fT4, pg/ml 13.2 ± 2.42 14.5 ± 3.83 14.6 ± 2.80 12.7 ± 1.95 12.3 ± 1.70 16.8 ± 2.70 15.1 ± 2.23 16.1 ± 3.09
TPOAb, U/ml 1,034 ± 830 704 ± 963 1,193 ± 1,031 955 ± 1,102 816 ± 866 1,061 ± 1,196 1,644 ± 2,168 1,124 ± 1,181
TgAb, U/ml 273 ± 530 147 ± 112 275 ± 478 198 ± 373 764 ± 1,066 737 ± 723 551 ± 684 395 ± 721
Thyroid volume, SDS 2.01 ± 2.00 2.14 ± 2.88 2.43 ± 2.00 1.12 ± 1.43 2.19 ± 3.16 1.87 ± 3.07 1.42 ± 2.90 1.30 ± 2.46







































 Fig. 2. Thyroid volume SDS (mean ± SE) in euthyroid children 
with HT. At the start of the study: n = 46 patients; at the end of the 
study: n = 20 patients. Open circles: treatment group with L-T4; 
closed circles: comparison group without L-T4. The numbers of 
patients in each group at the different examination points are 
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 Thyroid Volume 
 An enlarged thyroid volume >2.0 SDS was found at 
baseline in 47% of the individuals in the treatment group 
and in 24% of the individuals in the observation group. 
At the start of the study, the mean thyroid volume was 
slightly higher in the treatment group (2.5 SDS) than in 
the observation group (1.6 SDS). As shown in  figure 2 , 
there was a constant decline in the mean thyroid volume 
from 2.13 SDS (month 12) to 1.12 SDS (month 30) in the 
L-T4-treated group. The delta thyroid volume was –1.01 
SDS. In the observation group, the mean thyroid volume 
remained unchanged or slightly increased at the same pe-
riod from 1.73 to 2.0 SDS, with a delta thyroid volume of 
+0.27 SDS. Statistically, the change of the delta thyroid 
volume was significantly different between both groups 
during the 12- and 30-month time points (p < 0.05). 
However, comparing the thyroid volume (SDS) between 
both groups at each time point, we found no statistically 
significant difference. At the 36-month time point, the 
mean thyroid volume (SDS) was almost identical in both 
groups.
 Thyroid Function and Autoantibodies 
 Serum levels of fT4, TSH, TPOAb, and TgAb are 
shown in  figure 3 . At baseline, there was no difference in 





























































 Fig. 3. Serum thyroid hormones (mean ± SE) and autoantibodies (mean ± SE) in euthyroid children with HT 
during the course of the study. The patient numbers at the different examination points are shown in  figure 2 .
 a fT4 (pg/ml); fT4 pg/ml × 1.28 = pmol/l.  b TSH (mU/l).  c TPOAb (U/ml).  d TgAb (U/ml). Open circles/columns: 
treatment group with L-T4; closed circles/columns: comparison group without L-T4.  *  p < 0.05 
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and the observation group. After the start of L-T4 treat-
ment, mean fT4 levels significantly increased from 14.4 to 
19.8 pmol/l (p < 0.05) at month 6, whereas mean TSH 
levels significantly declined from 3.0 mU/ml at the start 
to 1.3 mU/ml (p < 0.05) at month 12. In the observation 
group without L-T4, both thyroid hormones remained 
unchanged during the study period. Significant differenc-
es between the treatment group and the observation 
group were found for serum fT4 levels at month 6 and for 
TSH levels at month 12 ( fig.  3 ). Thyroid antibodies 
showed a high variability. At baseline, both TPOAb and 
TgAb were positive in 80% of the individuals in the treat-
ment group and in 57% of those in the observation group. 
The rate of positive antibodies remained unchanged 
within both groups during the observation period. Serum 
TgAb levels were higher in the treatment group (signifi-
cant at months 6 and 18; p < 0.05) than in the observation 
group throughout the study period ( fig. 3 ).
 Longitudinal Data 
 The data of the patients with HT that were complete at 
36 months (n = 10) were analyzed longitudinally. The 
mean (±SD) age of the patients in the treatment group
(n = 10) was 10.6 ± 2.5 years, which was lower than in the 
observation group (n = 10; 13.4 ± 1.6 years). The clinical 
and laboratory characteristics were not different between 
the two groups except for lower TGAb levels in the obser-
vation group. The thyroid hormones and autoantibody 
levels of the 10 patients in each group at baseline, at 12 
and 24 months, and at the last visit were not significantly 
different ( table 2 ). The longitudinal analysis of the thy-
roid volume of the patients showed almost identical val-
ues at baseline. In the L-T4-treated group, there was a 
constant decline in the mean thyroid volume from the 
start to the 24-month time point (delta thyroid volume: 
–0.77 SDS), whereas the mean thyroid volume remained 
unchanged or slightly increased in the observation group 
 Table 3. Data from the literature on the effects of L-T4 treatment on the thyroid volume in children and adolescents with HT
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Radetti et al. [15], 2006 160 9.1 ± 3.6 2.72:1 – 5.0 Eu no
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Özen et al. [5], 2011 101 12.3 ± 2.9 5.7:1 +
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+ = Treatment with L-T4; – = treatment without L-T4; Eu = euthyroid; SH = subclinical hypothyroidism; Hypo = overt hypothyroidism; 
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(delta thyroid volume: +0.42). The change of the delta 
thyroid volume was significantly different between both 
groups from the start to the 24-month time point (p < 
0.05).
 Discussion 
 HT is the most common form of autoimmune thyroid 
disease in children and adolescents (female/male ratio 
approx. 4–5: 1), with an incidence of 0.1–5% per 100,000 
 [1, 2, 4] . At the time of diagnosis, most of the patients are 
euthyroid  [8, 15, 22, 23] . Controversy exists as to whether 
these euthyroid children and adolescents with HT (in 
particular those with goiter) require L-T4 therapy. There 
are only few studies in children with HT evaluating 
changes in thyroid volume ( table 3 ) following treatment 
with L-T4  [5, 10, 11, 14, 24] . In a retrospective study, the 
goiter size remained unchanged in all euthyroid patients 
with HT treated with L-T4  [14] . Svensson et al.  [11] stud-
ied a group of 35 euthyroid children with HT (n = 23 with 
goiter) during a median duration of L-T4 treatment of 2.8 
years and reported a reduction in the median thyroid vol-
ume from 2.5 SDS at baseline to 1.8 SDS at the final ultra-
sound examination. In euthyroid children without goiter, 
no change was noticed. The authors speculated that the 
reduction in thyroid size was more pronounced in en-
larged thyroid glands than in normal-sized ones. Scarpa 
et al.  [24] studied 50 euthyroid nongoitrous children and 
adolescents with HT for 2 years: 25 were randomized to 
receive L-T4, and 25 did not receive treatment. The chil-
dren with L-T4 had a further reduction in the thyroid 
volume after 2 years, whereas the thyroid size increased 
without L-T4 treatment. Özen et al.  [5] reported on a 
large number of patients with HT, but only 8 of 18 pa-
tients with goiter were treated with L-T4 at presentation. 
During follow-up ultrasounds, the size of the thyroid 
gland was found to be decreased or reverted to normal 
size in 7 patients, whereas no remarkable decrease was 
found in the group not receiving therapy. The latter find-
ing is in agreement with data reported from Thailand, 
where the goiter size remained unchanged during long-
term follow-up of euthyroid children with HT not treated 
with L-T4  [10] . However, the comparability of the report-
ed results is complicated due to various factors, such as 
small patient groups, different study design, and different 
methods of thyroid size measurement, and/or differences 
in reference data used for the interpretation of the results.
 The mean thyroid volume of our euthyroid patients 
with HT treated with L-T4 was 2.5 SDS at the start and 
1.3 SDS after 36 months. Our untreated comparison 
group also showed a reduction in thyroid size from 1.6 
SDS at enrolment to 1.1 SDS at the end of the 36-month 
observation period ( fig.  2 ). However, when using the 
36-month time point with almost identical thyroid vol-
umes in both groups, the conclusion that L-T4 has no ef-
fect on thyroid size is biased due to the small number of 
patients and the sudden loss of 6 patients in each group 
from the 30-month time point. At the 30-month time 
point, there are more patients and the thyroid volume fol-
lows the evolution at the earlier time points. Our data 
show a constant decline in the mean thyroid volume from 
2.13 SDS at month 12 to 1.12 SDS at month 30 in the 
L-T4-treated group. The delta thyroid volume was –1.01 
SDS, but it was +0.27 SDS in the observation group. Sta-
tistically, the change of the delta thyroid volume was sig-
nificantly different between both groups during the 12- 
and 30-month time points (p < 0.05). Our data show that 
the change in the delta thyroid volume is a better param-
eter to measure outcome than the thyroid volume.
 When analyzing the data only longitudinally for the 10 
patients in each group, we also found a constant decline 
in the mean thyroid volume of the L-T4-treated group 
from the start to the 24-month time point (delta thyroid 
volume: –0.77 SDS), whereas the mean thyroid volume 
remained unchanged or slightly increased in the observa-
tion group (delta thyroid volume: +0.42 SDS). The change 
of the delta thyroid volume was significantly different be-
tween both groups from the start to the 24-month time 
point (p < 0.05). The longitudinal data show that the ef-
fect of L-T4 therapy on the thyroid volume is limited to 
the first 2 years.
 Our data conform to a study performed according to 
our protocol in patients with type 1 diabetes mellitus and 
HT  [25] . This study was stopped at month 24 and also 
found no effect of L-T4 treatment on thyroid function 
and serum autoantibody levels. In our study, the L-T4 
dose was titrated to keep the TSH values within the nor-
mal range; accordingly, the dose was decreased in 4 pa-
tients and increased in 5. This therapeutic regimen was 
not associated with any changes in thyroid size and auto-
antibody levels. At the start of our study, the mean thy-
roid volume of the euthyroid patients treated with L-T4 
was almost identical with that of the group studied by 
Karges et al.  [25] (2.7 SDS at the start). Moreover, the 
mean thyroid volume reduction of –1.38 SDS after 30 
months in our treatment group was in the same range as 
in the group reported by Karges et al. after 24 months. We 
also found an increase in the thyroid volume in the obser-
vation group at 30 months (delta thyroid volume: +0.23 
 L-T4 Treatment of Euthyroid Children 
with Autoimmune HT 
Horm Res Paediatr 2015;84:266–274
DOI: 10.1159/000437140
273
SDS). The thyroid volume in the nontreated group re-
ported by Karges et al. increased to +1.1 SDS after 24 
months. In both studies, thyroid volume was determined 
by ultrasound, but different reference groups of iodine-
sufficient children were used for SDS calculations. For 
reference, we used the data of the German KIGGS Study 
 [19] , whereas Karges et al.  [25] used the data of a Berlin 
cohort of healthy school children published by Liesenköt-
ter et al.  [26] . One should also keep in mind that we stud-
ied euthyroid children with HT who were otherwise 
healthy, whereas Karges et al. studied euthyroid patients 
with HT and type 1 diabetes.
 Despite randomization of our patients, the patients in 
the treatment group had by chance a lower chronological 
age and a higher prevalence of an enlarged thyroid gland, 
but the main clinical characteristics of the patients were 
not different from those reported in other studies  [6, 27] . 
Our data show that TPOAb remained unchanged during 
the study period in both groups, whereas TgAb were lower 
in the observation group. Our data do not confirm other 
studies, particularly in adults, where a reduction of anti-
TPO and anti-Tg levels was reported during L-T4 treat-
ment  [28, 29] . The small amount of our data does not sup-
port the speculation that thyroid antibodies can be used as 
predictive factors for the course of the disease  [7, 30] . The 
proportion of our children (38%) who became subclini-
cally hypothyroid in the observation group was compara-
ble to other reported values of 12.5%  [5] and 42%  [24] .
 Unfortunately, our study ended prematurely (after 36 
instead of 60 months) with only one third of the enrolled 
patients meeting the protocol. We are aware that our re-
sults could be biased by the small number of patients. 
Therefore, the results of the study should be carefully in-
terpreted. Our data show that the delta thyroid volume 
change is a better parameter to measure outcome than 
thyroid volume and that the effect of L-T4 treatment on 
thyroid volume change depends on the time points cho-
sen. Taking all data together, we conclude that L-T4 treat-
ment does decrease the thyroid volume, but the effect is 
limited to a definite time period.
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In the article by Kim et al., entitled ‘Clinical and endocrine features of two Allan-Herndon-
Dudley syndrome patients with monocarboxylate transporter 8 mutations’ [Horm Res 
Paediatr 2015;83:288-292, DOI: 10.1159/000371466], the following errors occurred:
1. ‘p.I114N’ should be ‘p.I188N’ throughout the text.
2. In figure 1a, ‘c.341T>A (p.IIe114Asn)’ should be ‘c.563T>A (p.Ile188Asn)’, and in the 
accompanying legend as well as in the Case Reports section, ‘c.341T>A (p.I114N)’ 
should be ‘c.563T>A (p.I188N)’.
3. ‘Heterozygous’ should be ‘hemizygous’ throughout the text.
Please excuse any inconveniences caused.
